Fueling
Groundbreaking
Memory
Restoration
Learn More
RECALL
THERAPEUTICS
About Us
Recall Therapeutics has the only therapeutic focused on memory restoration for Alzheimer’s Disease
-
We are at Pre-IND stage with patent applications already filed
-
Our therapeutic has additional applications in Schizophrenia (Polydipsia) and Anxiety disorder
-
Our management team has deep medical experience and a track record of bringing drugs to market with multi-billion dollar exits via acquisition and IPO
The aging population is larger than it has ever been before
~11.2k
Americans
turn 65
every day
88.8 M
Projected number
of Americans
aged 65+ in 2060
Our life expectancies have increased nearly across every developed country in the globe
Over 7M people have some form of Dementia today in the US and 55M Globally.
The population size of seniors is unprecedented and society is searching for ways to care for them to support healthier, longer lives
Alzheimer’s disease is a key focus research area in tandem with this senior population boom
The number of people living with Alzheimer’s doubles every 5 years beyond the age of 65
+11 million unpaid caregivers provided ~18 billion hours of care to people with Alzheimer’s
In 2024, Alzheimer’s and other dementias will cost the nation $360B
Existing therapeutics in the market
are all focused on delaying memory loss,
not restoring memory
Newly approved drugs
are focused on amlyoid clearance,
which are non-memory aspects
At best,
these drugs simply delay memory loss, and show no restoration for memory
Current protocol
is an infusion
every 2 weeks with
horrible side effects
Patients are spending
~$30k a year on drugs
with minimal to
no improvement